EQ001 + EQ001 Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute-graft-versus-host Disease
Conditions
Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute
Trial Timeline
Jul 15, 2019 → Nov 21, 2022
NCT ID
NCT03763318About EQ001 + EQ001 Placebo
EQ001 + EQ001 Placebo is a phase 1/2 stage product being developed by Biocon for Acute-graft-versus-host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03763318. Target conditions include Acute-graft-versus-host Disease, aGVHD, GVHD.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04605926 | Phase 3 | Withdrawn |
| NCT03763318 | Phase 1/2 | Completed |
| NCT04007198 | Phase 1 | Completed |
Competing Products
2 competing products in Acute-graft-versus-host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AAT + Placebo | CSL | Phase 2/3 | 64 |
| Glassia | Kamada | Pre-clinical | 15 |